Anti-GD2 chimeric antigen receptor (CAR)-modified T cells may be a new and innovative approach for the treatment of pediatric H3-K27M-mutant diffuse midline gliomas.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jones, C. & Baker, S. J. Nat. Rev. Cancer 14, 651–661 (2014).
Mackay, A. et al. Cancer Cell 32, 520–537 (2017).
Lewis, P. W. et al. Science 340, 857–861 (2013).
Mount, C. W. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0006-x (2018).
Maude, S. L. et al. N. Engl. J. Med. 378, 439–448 (2018).
Ahmed, N. et al. JAMA Oncol. 3, 1094–1101 (2017).
O’Rourke, D. M. et al. Sci. Transl. Med. 9, eaaa0984 (2017).
Brown, C. E. et al. N. Engl. J. Med. 375, 2561–2569 (2016).
Yu, A. L. et al. N. Engl. J. Med. 363, 1324–1334 (2010).
Waligora, M. et al. PLoS Med. 15, e1002505 (2018).
Grasso, C. S. et al. Nat. Med. 21, 827 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Ramaswamy, V., Taylor, M.D. CAR T cells for childhood diffuse midline gliomas. Nat Med 24, 534–535 (2018). https://doi.org/10.1038/s41591-018-0031-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0031-9
